Interaction Checker

Pomalidomide interactions

Pomalidomide (Pomalyst) has 29 documented interactions across the FDA labels and fact sheets we index: 9 major, 20 moderate, 0 minor, and 0 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Interactions from the label

Major interactions (9)

  • Cannabidiol (prescription)anticonvulsantMajor

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (Pomalidomide label, Drug interactions)

  • CimetidineH2 blockerMajor

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (Pomalidomide label, Drug interactions)

  • CiprofloxacinfluoroquinoloneMajor

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (Pomalidomide label, Drug interactions)

  • Deferasiroxiron supplementMajor

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (Pomalidomide label, Drug interactions)

  • DexamethasonecorticosteroidMajor

    Treatment of patients with MM with a PD-1 or PD-L1 blocking antibody in combination with a thalidomide analogue plus dexamethasone is not recommended outside of controlled clinical trials. (Pomalidomide label, Warnings and precautions)

  • FluvoxamineSSRIMajor

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (Pomalidomide label, Drug interactions)

  • MexiletineantiarrhythmicMajor

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (Pomalidomide label, Drug interactions)

  • Viloxazinenorepinephrine reuptake inhibitorMajor

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (Pomalidomide label, Drug interactions)

  • ZileutonCYP1A2 inhibitorMajor

    Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. (Pomalidomide label, Drug interactions)

Moderate interactions (20)

  • ApixabananticoagulantModerate

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (Pomalidomide label, Warnings and precautions)

  • ArgatrobananticoagulantModerate

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (Pomalidomide label, Warnings and precautions)

  • BivalirudinanticoagulantModerate

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (Pomalidomide label, Warnings and precautions)

  • DabigatrananticoagulantModerate

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (Pomalidomide label, Warnings and precautions)

  • Desogestrel and ethinyl estradioloral contraceptiveModerate

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (Pomalidomide label, Warnings and precautions)

  • Drospirenone and ethinyl estradioloral contraceptiveModerate

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (Pomalidomide label, Warnings and precautions)

  • EdoxabananticoagulantModerate

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (Pomalidomide label, Warnings and precautions)

  • EnoxaparinanticoagulantModerate

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (Pomalidomide label, Warnings and precautions)

  • Estradiol and dienogestoral contraceptiveModerate

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (Pomalidomide label, Warnings and precautions)

  • Ethynodiol diacetate and ethinyl estradioloral contraceptiveModerate

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (Pomalidomide label, Warnings and precautions)

  • FondaparinuxanticoagulantModerate

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (Pomalidomide label, Warnings and precautions)

  • HeparinanticoagulantModerate

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (Pomalidomide label, Warnings and precautions)

  • Levonorgestrel and ethinyl estradioloral contraceptiveModerate

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (Pomalidomide label, Warnings and precautions)

  • NorethindroneprogestinModerate

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (Pomalidomide label, Warnings and precautions)

  • Norethindrone and ethinyl estradioloral contraceptiveModerate

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (Pomalidomide label, Warnings and precautions)

  • Norgestimate and ethinyl estradioloral contraceptiveModerate

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (Pomalidomide label, Warnings and precautions)

  • Norgestrel and ethinyl estradioloral contraceptiveModerate

    Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. (Pomalidomide label, Warnings and precautions)

  • RivaroxabananticoagulantModerate

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (Pomalidomide label, Warnings and precautions)

  • Tobacco and smokingTobacco and cannabisModerate

    Patients with known risk factors, including prior thrombosis, may be at greater risk, and actions should be taken to try to minimize all modifiable factors (e.g., hyperlipidemia, hypertension, smoking). (Pomalidomide label, Warnings and precautions)

  • WarfarinanticoagulantModerate

    In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. (Pomalidomide label, Warnings and precautions)

Check Pomalidomide against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.